143 related articles for article (PubMed ID: 30048162)
1. New and emerging drug therapies for Cushing's disease.
Störmann S; Schopohl J
Expert Opin Pharmacother; 2018 Aug; 19(11):1187-1200. PubMed ID: 30048162
[TBL] [Abstract][Full Text] [Related]
2. Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies.
Fleseriu M; Castinetti F
Pituitary; 2016 Dec; 19(6):643-653. PubMed ID: 27600150
[TBL] [Abstract][Full Text] [Related]
3. Advances in the medical treatment of Cushing's syndrome.
Feelders RA; Newell-Price J; Pivonello R; Nieman LK; Hofland LJ; Lacroix A
Lancet Diabetes Endocrinol; 2019 Apr; 7(4):300-312. PubMed ID: 30033041
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic compounds for Cushing's syndrome: a patent review (2012-2016).
Ma L; Yin L; Hu Q
Expert Opin Ther Pat; 2016 Nov; 26(11):1307-1323. PubMed ID: 27454103
[TBL] [Abstract][Full Text] [Related]
5. Cushing's disease: adrenal steroidogenesis inhibitors.
Pivonello R; Simeoli C; Di Paola N; Colao A
Pituitary; 2022 Oct; 25(5):726-732. PubMed ID: 36036308
[TBL] [Abstract][Full Text] [Related]
6. Cushing's syndrome: an update on current pharmacotherapy and future directions.
Creemers SG; Hofland LJ; Lamberts SW; Feelders RA
Expert Opin Pharmacother; 2015; 16(12):1829-44. PubMed ID: 26133755
[TBL] [Abstract][Full Text] [Related]
7. Cushing's disease: current medical therapies and molecular insights guiding future therapies.
Lau D; Rutledge C; Aghi MK
Neurosurg Focus; 2015 Feb; 38(2):E11. PubMed ID: 25639313
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of pharmacological options for Cushing's disease: what are the state-of-the-art options?
Martino M; Aboud N; Lucchetti B; Salvio G; Arnaldi G
Expert Opin Pharmacother; 2023 Apr; 24(5):557-576. PubMed ID: 36927238
[TBL] [Abstract][Full Text] [Related]
9. Drugs in the medical treatment of Cushing's syndrome.
Schteingart DE
Expert Opin Emerg Drugs; 2009 Dec; 14(4):661-71. PubMed ID: 19939210
[TBL] [Abstract][Full Text] [Related]
10. Cushing's syndrome: from physiological principles to diagnosis and clinical care.
Raff H; Carroll T
J Physiol; 2015 Feb; 593(3):493-506. PubMed ID: 25480800
[TBL] [Abstract][Full Text] [Related]
11. Medical Management of Cushing's Syndrome: Current and Emerging Treatments.
Hinojosa-Amaya JM; Cuevas-Ramos D; Fleseriu M
Drugs; 2019 Jun; 79(9):935-956. PubMed ID: 31098899
[TBL] [Abstract][Full Text] [Related]
12. Evaluation and treatment of Cushing's syndrome.
Nieman LK; Ilias I
Am J Med; 2005 Dec; 118(12):1340-6. PubMed ID: 16378774
[TBL] [Abstract][Full Text] [Related]
13. Prolonged adrenal insufficiency following discontinuation of osilodrostat treatment for intense hypercortisolism.
Ferriere A; Salenave S; Puerto M; Young J; Tabarin A
Eur J Endocrinol; 2024 Jan; 190(1):L1-L3. PubMed ID: 38123490
[TBL] [Abstract][Full Text] [Related]
14. Osilodrostat oral tablets for adults with Cushing's disease.
Martino M; Aboud N; Lucchetti B; Salvio G; Arnaldi G
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):99-109. PubMed ID: 35220871
[TBL] [Abstract][Full Text] [Related]
15. Approach to the Patient Treated with Steroidogenesis Inhibitors.
Castinetti F; Nieman LK; Reincke M; Newell-Price J
J Clin Endocrinol Metab; 2021 Jun; 106(7):2114-2123. PubMed ID: 33675650
[TBL] [Abstract][Full Text] [Related]
16. Pitfalls in the diagnosis and management of Cushing's syndrome.
Bansal V; El Asmar N; Selman WR; Arafah BM
Neurosurg Focus; 2015 Feb; 38(2):E4. PubMed ID: 25639322
[TBL] [Abstract][Full Text] [Related]
17. Mifepristone (RU 486) in Cushing's syndrome.
Johanssen S; Allolio B
Eur J Endocrinol; 2007 Nov; 157(5):561-9. PubMed ID: 17984235
[TBL] [Abstract][Full Text] [Related]
18. Systematic analysis of G protein-coupled receptor gene expression in adrenocorticotropin-independent macronodular adrenocortical hyperplasia identifies novel targets for pharmacological control of adrenal Cushing's syndrome.
Assie G; Louiset E; Sturm N; René-Corail F; Groussin L; Bertherat J; Thomas M; Lefebvre H; Feige JJ; Clauser E; Chabre O; Cherradi N
J Clin Endocrinol Metab; 2010 Oct; 95(10):E253-62. PubMed ID: 20660048
[TBL] [Abstract][Full Text] [Related]
19. Cushing's disease.
Bertagna X; Guignat L; Groussin L; Bertherat J
Best Pract Res Clin Endocrinol Metab; 2009 Oct; 23(5):607-23. PubMed ID: 19945026
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome.
Aron DC; Raff H; Findling JW
J Clin Endocrinol Metab; 1997 Jun; 82(6):1780-5. PubMed ID: 9177382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
